Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Epithelial splicing regulator protein 1 and alternative splicing in somatotroph adenomas.

Lekva T, Berg JP, Lyle R, Heck A, Ringstad G, Olstad OK, Michelsen AE, Casar-Borota O, Bollerslev J, Ueland T.

Endocrinology. 2013 Sep;154(9):3331-43. doi: 10.1210/en.2013-1051. Epub 2013 Jul 3.

PMID:
23825128
2.

Gene expression profiling identifies ESRP1 as a potential regulator of epithelial mesenchymal transition in somatotroph adenomas from a large cohort of patients with acromegaly.

Lekva T, Berg JP, Fougner SL, Olstad OK, Ueland T, Bollerslev J.

J Clin Endocrinol Metab. 2012 Aug;97(8):E1506-14. doi: 10.1210/jc.2012-1760. Epub 2012 May 14.

PMID:
22585092
3.

Alternative splicing of placental lactogen (CSH2) in somatotroph pituitary adenomas.

Lekva T, Berg JP, Lyle R, Heck A, Bollerslev J, Ueland T.

Neuro Endocrinol Lett. 2015;36(2):136-42.

PMID:
26071582
4.

Attenuated RORC expression in the presence of EMT progression in somatotroph adenomas following treatment with somatostatin analogs is associated with poor clinical recovery.

Lekva T, Berg JP, Heck A, Lyngvi Fougner S, Olstad OK, Ringstad G, Bollerslev J, Ueland T.

PLoS One. 2013 Jun 25;8(6):e66927. doi: 10.1371/journal.pone.0066927. Print 2013.

5.

Characterization of SNARE proteins in human pituitary adenomas: targeted secretion inhibitors as a new strategy for the treatment of acromegaly?

Garcia EA, Trivellin G, Aflorei ED, Powell M, Grieve J, Alusi G, Pobereskin L, Shariati B, Cudlip S, Roncaroli F, Mendoza N, Grossman AB, Harper EA, Korbonits M.

J Clin Endocrinol Metab. 2013 Dec;98(12):E1918-26. doi: 10.1210/jc.2013-2602. Epub 2013 Oct 23.

PMID:
24152687
6.

STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion.

Zhou C, Jiao Y, Wang R, Ren SG, Wawrowsky K, Melmed S.

J Clin Invest. 2015 Apr;125(4):1692-702. doi: 10.1172/JCI78173. Epub 2015 Mar 16.

7.

The aging suppressor klotho: a potential regulator of growth hormone secretion.

Shahmoon S, Rubinfeld H, Wolf I, Cohen ZR, Hadani M, Shimon I, Rubinek T.

Am J Physiol Endocrinol Metab. 2014 Aug 1;307(3):E326-34. doi: 10.1152/ajpendo.00090.2014. Epub 2014 Jun 17.

8.

Clinically silent somatotroph adenomas are common.

Wade AN, Baccon J, Grady MS, Judy KD, O'Rourke DM, Snyder PJ.

Eur J Endocrinol. 2011 Jul;165(1):39-44. doi: 10.1530/EJE-11-0216. Epub 2011 Apr 14.

9.

Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.

Chahal HS, Trivellin G, Leontiou CA, Alband N, Fowkes RC, Tahir A, Igreja SC, Chapple JP, Jordan S, Lupp A, Schulz S, Ansorge O, Karavitaki N, Carlsen E, Wass JA, Grossman AB, Korbonits M.

J Clin Endocrinol Metab. 2012 Aug;97(8):E1411-20. doi: 10.1210/jc.2012-1111. Epub 2012 Jun 1.

PMID:
22659247
10.

Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor.

Kola B, Korbonits M, Diaz-Cano S, Kaltsas G, Morris DG, Jordan S, Metherell L, Powell M, Czirják S, Arnaldi G, Bustin S, Boscaro M, Mantero F, Grossman AB.

Clin Endocrinol (Oxf). 2003 Sep;59(3):328-38.

PMID:
12919156
11.

DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours.

Plöckinger U, Hoffmann U, Geese M, Lupp A, Buchfelder M, Flitsch J, Vajkoczy P, Jakob W, Saeger W, Schulz S, Dohrmann C.

Eur J Endocrinol. 2012 Feb;166(2):223-34. doi: 10.1530/EJE-11-0737. Epub 2011 Nov 7.

12.

Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas.

Mayr B, Buslei R, Theodoropoulou M, Stalla GK, Buchfelder M, Schöfl C.

Eur J Endocrinol. 2013 Sep 12;169(4):391-400. doi: 10.1530/EJE-13-0134. Print 2013 Oct.

13.

Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.

Ibáñez-Costa A, Rivero-Cortés E, Vázquez-Borrego MC, Gahete MD, Jiménez-Reina L, Venegas-Moreno E, de la Riva A, Arráez MÁ, González-Molero I, Schmid HA, Maraver-Selfa S, Gavilán-Villarejo I, García-Arnés JA, Japón MA, Soto-Moreno A, Gálvez MA, Luque RM, Castaño JP.

J Endocrinol. 2016 Nov;231(2):135-145. Epub 2016 Sep 1.

PMID:
27587848
14.

Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment.

Fougner SL, Bollerslev J, Latif F, Hald JK, Lund T, Ramm-Pettersen J, Berg JP.

J Clin Endocrinol Metab. 2008 Apr;93(4):1211-6. doi: 10.1210/jc.2007-2272. Epub 2008 Jan 29.

PMID:
18230656
15.

Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide.

Casar-Borota O, Heck A, Schulz S, Nesland JM, Ramm-Pettersen J, Lekva T, Alafuzoff I, Bollerslev J.

J Clin Endocrinol Metab. 2013 Nov;98(11):E1730-9. doi: 10.1210/jc.2013-2145. Epub 2013 Oct 3.

PMID:
24092823
16.

Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.

Zatelli MC, Piccin D, Tagliati F, Bottoni A, Ambrosio MR, Margutti A, Scanarini M, Bondanelli M, Culler MD, degli Uberti EC.

J Mol Endocrinol. 2005 Oct;35(2):333-41.

PMID:
16216913
17.

The expression of ghrelin in somatotroph and other types of pituitary adenomas.

Wasko R, Jaskula M, Kotwicka M, Andrusiewicz M, Jankowska A, Liebert W, Sowinski J.

Neuro Endocrinol Lett. 2008 Dec;29(6):929-38.

PMID:
19112387
18.

Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas.

Padova H, Rubinfeld H, Hadani M, Cohen ZR, Nass D, Taylor JE, Culler MD, Shimon I.

Mol Cell Endocrinol. 2008 May 14;286(1-2):214-8. doi: 10.1016/j.mce.2007.12.011. Epub 2007 Dec 27.

PMID:
18276067
19.

Augmented Growth Hormone Secretion and Stat3 Phosphorylation in an Aryl Hydrocarbon Receptor Interacting Protein (AIP)-Disrupted Somatotroph Cell Line.

Fukuda T, Tanaka T, Hamaguchi Y, Kawanami T, Nomiyama T, Yanase T.

PLoS One. 2016 Oct 5;11(10):e0164131. doi: 10.1371/journal.pone.0164131. eCollection 2016.

20.

Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation.

Sakai N, Kim K, Sanno N, Yoshida D, Teramoto A, Shibasaki T.

Neurol Med Chir (Tokyo). 2008;48(11):481-7; discussion 487-8.

Supplemental Content

Support Center